SCHEMBL408088

SCHEMBL408088

O=C(O)N1CCc2[nH]c3ncc(Cl)cc3c2C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BAZ2B Q9UIF8 12/20 0.52
MAPT P10636 3/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
MCL1 Q07820 1/20 0.45
CGAS Q8N884 1/20 0.44
GAA P10253 1/20 0.43
ALOX15 P16050 1/20 0.43
ALOX12 P18054 1/20 0.43
MAPK1 P28482 1/20 0.43
CASP1 P29466 1/20 0.43
CASP7 P55210 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
LMNA P02545 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10139827 0.86 CFTR (0.52) BAZ2BMAPTMEN1KMT2ACYP1A2
Hydrochloric Acid SCHEMBL406670 0.85 CFTR (0.51) BAZ2BMAPTMEN1KMT2ACYP1A2
SCHEMBL10139825 0.85 BAZ2B (0.53) BAZ2BMAPTMEN1KMT2ACYP1A2
Hydrochloric Acid SCHEMBL407664 0.84 BAZ2B (0.52) BAZ2BMAPTMEN1KMT2ACYP1A2
SCHEMBL404753 0.83 BAZ2B (0.48) BAZ2BMAPTMEN1KMT2ACYP1A2
SCHEMBL10139873 0.83 MEN1 (0.69) BAZ2BMAPTMEN1KMT2ACYP1A2
SCHEMBL10139838 0.82 BAZ2B (0.50) BAZ2BMAPTMEN1KMT2ACYP1A2
SCHEMBL10139831 0.82 LMNA (0.48) BAZ2BMAPTMEN1KMT2ACYP1A2
Hydrochloric Acid SCHEMBL408386 0.81 BAZ2B (0.49) BAZ2BMAPTMEN1KMT2ACYP1A2
Hydrochloric Acid SCHEMBL405834 0.81 LMNA (0.47) BAZ2BMAPTMEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2367822-B1 TRICYCLIC AZAINDOLES MERCK PATENT GMBH (DE) 2016-10-05 EP claimed
US-8853391-B2 Tricyclic azaindoles MERCK PATENT GMBH (DE) 2014-10-07 US claimed
US-20120022060-A1 Tricyclic Azaindoles MERCK PATENT GMBH (DE) 2012-01-26 US claimed
EP-2367822-A1 TRICYCLIC AZAINDOLES Merck Patent GmbH (DE) 2011-09-28 EP claimed
WO-2010080253-A1 TRICYCLIC AZAINDOLES MERCK PATENT GMBH (DE) 2010-07-15 WO claimed
EP-2367822-B1 TRICYCLIC AZAINDOLES MERCK PATENT GMBH (DE) 2016-10-05 EP disclosed
US-8853391-B2 Tricyclic azaindoles MERCK PATENT GMBH (DE) 2014-10-07 US disclosed
US-20120022060-A1 Tricyclic Azaindoles MERCK PATENT GMBH (DE) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022060-A1 Tricyclic Azaindoles AZI2, DCK, PPP2CA BAZ2B 506/4885MAPT 2520/4885MEN1 3463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.